Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Пациент после инфаркта миокарда: как снизить риск повторного ишемического события?
Пациент после инфаркта миокарда: как снизить риск повторного ишемического события?
Барбараш О.Л., Каретникова В.Н., Кашталап В.В. Пациент после инфаркта миокарда: как снизить риск повторного ишемического события? КардиоСоматика. 2015; 6 (2): 12–19.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье обсуждены проблемы низкой выживаемости пациентов после перенесенного инфаркта миокарда (ИМ), а также факторы, влияющие на этот показатель. Обозначена в качестве приоритетной проблема приверженности пациентов терапии после перенесенного острого коронарного события, определены возможности ее улучшения, а также перспективны оптимизации медикаментозного лечения пациента после ИМ, в частности, необходимость пролонгированной двойной антитромботической терапии (ДАТТ). Обоснованием для изменения текущих рекомендаций по ведению пациентов с острыми коронарными синдромами могут быть результаты недавно закончившегося международного клинического исследования PEGASUS-TIMI 54 c тикагрелором (Брилинта®) в качестве второго компонента ДАТТ, продемонстрировавшие эффективность и безопасность пролонгации ДАТТ после 12 мес постинфарктного периода.
Ключевые слова: профилактика инфаркта миокарда, двойная антитромбоцитарная терапия, тикагрелор.
Key words: prevention of myocardial infarction, dual antiplatelet therapy, ticagrelor.
Ключевые слова: профилактика инфаркта миокарда, двойная антитромбоцитарная терапия, тикагрелор.
________________________________________________
Key words: prevention of myocardial infarction, dual antiplatelet therapy, ticagrelor.
Полный текст
Список литературы
1. Бойцов С.А. Профилактика неинфекционных заболеваний в стране: от «что делать» к «как делать». Профилактическая медицина. 2012; 2: 3–10. / Boitsov S.A. Profilaktika neinfektsionnykh zabolevanii v strane: ot «chto delat'» k «kak delat'». Profilakticheskaia meditsina. 2012; 2: 3–10. [in Russian]
2. Россия 2014: Стат. справочник. Р76 Росстат. М., 2014. / Rossiia 2014: Stat. spravochnik. R76 Rosstat. M., 2014. [in Russian]
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028–34.
5. Sanfelix-Gimeno G, Peiro S, Ferreros I et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. JMCP 2013; 3 (19): 247–57.
6. Kostis WJ, Deng Y, Pantazopoulos JS et al. For the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes 2010; 3: 581–9.
7. Chung SC, Gedeborg R, Nicholas O et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and in the UK. Lancet 2014; 383: 1305–12.
8. Shah NS, Huffman MD, Ning H, Llloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999–2012. J American Heart Association. 2015; 4: 1–12.
9. Peeters A, Mamun AA, Willekens F, Bonneux L for NEDCOM. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66.
10. Smolina K, Wright FL, Rayner M, Goldacre MG. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes 2012; 5: 532–40.
11. Bhatt DL, Eagle KA, Ohman EM et al for the REACH Registry Investigators. JAMA. 2010; 304 (12): 1350–7.
12. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J doi: 10.1093/eurheartj/ehu505.
13. Sorenzen R, Gislason GH, Fosbol EL et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66: 875–84.
14. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8.
15. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376162 patients. Am J Med 2012; 9 (125): 882–7.
16. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755–64.
17. Каретникова В.Н., Евсеева М.В., Калаева В.В и др. Почечная дисфункция при инфаркте миокарда с подъемом сегмента ST: факторы риска, влияние на прогноз. Сердце. 2014 (80); 6: 339–46. / Karetnikova V.N., Evseeva M.V., Kalaeva V.V i dr. Pochechnaia disfunktsiia pri infarkte miokarda s pod"emom segmenta ST: faktory riska, vliianie na prognoz. Serdtse. 2014 (80); 6: 339–46. [in Russian]
18. Каретникова В.Н., Зыков М.В., Кашталап В.В. и др. Значение почечной дисфункции для госпитального прогноза больных инфарктом миокарда с подъемом сегмента ST. Сердце. 2013 (73); 5: 50–6. / Karetnikova V.N., Zykov M.V., Kashtalap V.V. i dr. Znachenie pochechnoi disfunktsii dlia gospital'nogo prognoza bol'nykh infarktom miokarda s pod"emom segmenta ST. Serdtse. 2013 (73); 5: 50–6. [in Russian]
19. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5.
20. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495–504.
21. Rex S et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97–110.
22. Бурячковская Л.И., Сумароков А.Б., Учитель И.А., Гупало Е.М. Противовоспалительное действие клопидогрела при атеросклерозе. Рациональная фармакотерапия в кардиологии. 2011; 7 (6): 677–84. / Buriachkovskaia L.I., Sumarokov A.B., Uchitel' I.A., Gupalo E.M. Protivovospalitel'noe deistvie klopidogrela pri ateroskleroza. Ratsional'naia farmakoterapiia v kardiologii. 2011; 7 (6): 677–84. [in Russian]
23. Solheim S et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–4.
24. Chen YG et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–6.
25. O,Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. Circulation 2013; 127 (4): e362–e425.
26. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–619.
27. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
28. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
29. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966–72.
30. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028–33.
31. Park SJ, Park DW, Kim YH et al. Duration of antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374–82.
32. Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3): 304–12.
33. Valgimigli M, Campo G, Monti M et al. Short-versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015–26.
34. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982–8.
35. Cavender MA, Scirica BM, Bonaca MP et al. Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2 P-TIMI 50 Trial. doi: 10.1161/CIRCULATIONAHA.114.013774.
36. Chin CT, Roe MT, Fox KA et al. Study design and rationale of a comparison of prasugrel andclopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16–22.
37. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088–92.
38. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.
39. Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug-eluting stent impantation. J Am Coll Cardiol 2015; 65 (13): 1298–10.
40. Gilard M, Barragan P, Noryani AA et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015; 65: 777–86.
41. Эрлих А.Д. Двойная антитромбоцитарная терапия: необходимость приверженности к лечению и возможности ее повышения. Атеротромбоз. 2014; 2: 25–33. / Erlikh A.D. Dvoinaia antitrombotsitarnaia terapiia: neobkhodimost' priverzhennosti k lecheniiu i vozmozhnosti ee povysheniia. Aterotromboz. 2014; 2: 25–33. [in Russian]
42. Bonaca MP, Bhatt D., Cohen M et al for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.
43. Bonaca MP, Bhatt D, Braunwald E et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437–444.e5.
44. Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии. 2013; 9 (5): 49–9. / Tolpygina S.N., Polianskaia Iu.N., Martsevich S.Iu. Lechenie patsientov s khronicheskoi IBS v real'noi klinicheskoi praktike po dannym registra PROGNOZ IBS (chast' 2). Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (5): 49–9. [in Russian]
2. Rossiia 2014: Stat. spravochnik. R76 Rosstat. M., 2014. [in Russian]
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028–34.
5. Sanfelix-Gimeno G, Peiro S, Ferreros I et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. JMCP 2013; 3 (19): 247–57.
6. Kostis WJ, Deng Y, Pantazopoulos JS et al. For the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes 2010; 3: 581–9.
7. Chung SC, Gedeborg R, Nicholas O et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and in the UK. Lancet 2014; 383: 1305–12.
8. Shah NS, Huffman MD, Ning H, Llloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999–2012. J American Heart Association. 2015; 4: 1–12.
9. Peeters A, Mamun AA, Willekens F, Bonneux L for NEDCOM. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66.
10. Smolina K, Wright FL, Rayner M, Goldacre MG. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes 2012; 5: 532–40.
11. Bhatt DL, Eagle KA, Ohman EM et al for the REACH Registry Investigators. JAMA. 2010; 304 (12): 1350–7.
12. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J doi: 10.1093/eurheartj/ehu505.
13. Sorenzen R, Gislason GH, Fosbol EL et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66: 875–84.
14. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8.
15. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376162 patients. Am J Med 2012; 9 (125): 882–7.
16. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755–64.
17. Karetnikova V.N., Evseeva M.V., Kalaeva V.V i dr. Pochechnaia disfunktsiia pri infarkte miokarda s pod"emom segmenta ST: faktory riska, vliianie na prognoz. Serdtse. 2014 (80); 6: 339–46. [in Russian]
18. Karetnikova V.N., Zykov M.V., Kashtalap V.V. i dr. Znachenie pochechnoi disfunktsii dlia gospital'nogo prognoza bol'nykh infarktom miokarda s pod"emom segmenta ST. Serdtse. 2013 (73); 5: 50–6. [in Russian]
19. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5.
20. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495–504.
21. Rex S et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97–110.
22. Buriachkovskaia L.I., Sumarokov A.B., Uchitel' I.A., Gupalo E.M. Protivovospalitel'noe deistvie klopidogrela pri ateroskleroza. Ratsional'naia farmakoterapiia v kardiologii. 2011; 7 (6): 677–84. [in Russian]
23. Solheim S et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–4.
24. Chen YG et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–6.
25. O,Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. Circulation 2013; 127 (4): e362–e425.
26. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–619.
27. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
28. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
29. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966–72.
30. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028–33.
31. Park SJ, Park DW, Kim YH et al. Duration of antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374–82.
32. Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3): 304–12.
33. Valgimigli M, Campo G, Monti M et al. Short-versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015–26.
34. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982–8.
35. Cavender MA, Scirica BM, Bonaca MP et al. Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2 P-TIMI 50 Trial. doi: 10.1161/CIRCULATIONAHA.114.013774.
36. Chin CT, Roe MT, Fox KA et al. Study design and rationale of a comparison of prasugrel andclopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16–22.
37. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088–92.
38. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.
39. Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug-eluting stent impantation. J Am Coll Cardiol 2015; 65 (13): 1298–10.
40. Gilard M, Barragan P, Noryani AA et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015; 65: 777–86.
41. Erlikh A.D. Dvoinaia antitrombotsitarnaia terapiia: neobkhodimost' priverzhennosti k lecheniiu i vozmozhnosti ee povysheniia. Aterotromboz. 2014; 2: 25–33. [in Russian]
42. Bonaca MP, Bhatt D., Cohen M et al for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.
43. Bonaca MP, Bhatt D, Braunwald E et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437–444.e5.
44. Tolpygina S.N., Polianskaia Iu.N., Martsevich S.Iu. Lechenie patsientov s khronicheskoi IBS v real'noi klinicheskoi praktike po dannym registra PROGNOZ IBS (chast' 2). Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (5): 49–9. [in Russian]
2. Россия 2014: Стат. справочник. Р76 Росстат. М., 2014. / Rossiia 2014: Stat. spravochnik. R76 Rosstat. M., 2014. [in Russian]
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028–34.
5. Sanfelix-Gimeno G, Peiro S, Ferreros I et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. JMCP 2013; 3 (19): 247–57.
6. Kostis WJ, Deng Y, Pantazopoulos JS et al. For the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes 2010; 3: 581–9.
7. Chung SC, Gedeborg R, Nicholas O et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and in the UK. Lancet 2014; 383: 1305–12.
8. Shah NS, Huffman MD, Ning H, Llloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999–2012. J American Heart Association. 2015; 4: 1–12.
9. Peeters A, Mamun AA, Willekens F, Bonneux L for NEDCOM. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66.
10. Smolina K, Wright FL, Rayner M, Goldacre MG. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes 2012; 5: 532–40.
11. Bhatt DL, Eagle KA, Ohman EM et al for the REACH Registry Investigators. JAMA. 2010; 304 (12): 1350–7.
12. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J doi: 10.1093/eurheartj/ehu505.
13. Sorenzen R, Gislason GH, Fosbol EL et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66: 875–84.
14. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8.
15. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376162 patients. Am J Med 2012; 9 (125): 882–7.
16. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755–64.
17. Каретникова В.Н., Евсеева М.В., Калаева В.В и др. Почечная дисфункция при инфаркте миокарда с подъемом сегмента ST: факторы риска, влияние на прогноз. Сердце. 2014 (80); 6: 339–46. / Karetnikova V.N., Evseeva M.V., Kalaeva V.V i dr. Pochechnaia disfunktsiia pri infarkte miokarda s pod"emom segmenta ST: faktory riska, vliianie na prognoz. Serdtse. 2014 (80); 6: 339–46. [in Russian]
18. Каретникова В.Н., Зыков М.В., Кашталап В.В. и др. Значение почечной дисфункции для госпитального прогноза больных инфарктом миокарда с подъемом сегмента ST. Сердце. 2013 (73); 5: 50–6. / Karetnikova V.N., Zykov M.V., Kashtalap V.V. i dr. Znachenie pochechnoi disfunktsii dlia gospital'nogo prognoza bol'nykh infarktom miokarda s pod"emom segmenta ST. Serdtse. 2013 (73); 5: 50–6. [in Russian]
19. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5.
20. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495–504.
21. Rex S et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97–110.
22. Бурячковская Л.И., Сумароков А.Б., Учитель И.А., Гупало Е.М. Противовоспалительное действие клопидогрела при атеросклерозе. Рациональная фармакотерапия в кардиологии. 2011; 7 (6): 677–84. / Buriachkovskaia L.I., Sumarokov A.B., Uchitel' I.A., Gupalo E.M. Protivovospalitel'noe deistvie klopidogrela pri ateroskleroza. Ratsional'naia farmakoterapiia v kardiologii. 2011; 7 (6): 677–84. [in Russian]
23. Solheim S et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–4.
24. Chen YG et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–6.
25. O,Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. Circulation 2013; 127 (4): e362–e425.
26. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–619.
27. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
28. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
29. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966–72.
30. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028–33.
31. Park SJ, Park DW, Kim YH et al. Duration of antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374–82.
32. Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3): 304–12.
33. Valgimigli M, Campo G, Monti M et al. Short-versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015–26.
34. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982–8.
35. Cavender MA, Scirica BM, Bonaca MP et al. Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2 P-TIMI 50 Trial. doi: 10.1161/CIRCULATIONAHA.114.013774.
36. Chin CT, Roe MT, Fox KA et al. Study design and rationale of a comparison of prasugrel andclopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16–22.
37. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088–92.
38. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.
39. Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug-eluting stent impantation. J Am Coll Cardiol 2015; 65 (13): 1298–10.
40. Gilard M, Barragan P, Noryani AA et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015; 65: 777–86.
41. Эрлих А.Д. Двойная антитромбоцитарная терапия: необходимость приверженности к лечению и возможности ее повышения. Атеротромбоз. 2014; 2: 25–33. / Erlikh A.D. Dvoinaia antitrombotsitarnaia terapiia: neobkhodimost' priverzhennosti k lecheniiu i vozmozhnosti ee povysheniia. Aterotromboz. 2014; 2: 25–33. [in Russian]
42. Bonaca MP, Bhatt D., Cohen M et al for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.
43. Bonaca MP, Bhatt D, Braunwald E et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437–444.e5.
44. Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии. 2013; 9 (5): 49–9. / Tolpygina S.N., Polianskaia Iu.N., Martsevich S.Iu. Lechenie patsientov s khronicheskoi IBS v real'noi klinicheskoi praktike po dannym registra PROGNOZ IBS (chast' 2). Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (5): 49–9. [in Russian]
________________________________________________
2. Rossiia 2014: Stat. spravochnik. R76 Rosstat. M., 2014. [in Russian]
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med 2011; 3: e442.
4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028–34.
5. Sanfelix-Gimeno G, Peiro S, Ferreros I et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information system in Valencia, Spain. JMCP 2013; 3 (19): 247–57.
6. Kostis WJ, Deng Y, Pantazopoulos JS et al. For the MIDAS14 Study group. Circ Cardiovascular Qual Outcomes 2010; 3: 581–9.
7. Chung SC, Gedeborg R, Nicholas O et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and in the UK. Lancet 2014; 383: 1305–12.
8. Shah NS, Huffman MD, Ning H, Llloyd-Jones DM. Trends in myocardial infarction secondary prevention: The National Health and Nutritional Examination Survey (NHANES), 1999–2012. J American Heart Association. 2015; 4: 1–12.
9. Peeters A, Mamun AA, Willekens F, Bonneux L for NEDCOM. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002; 23: 458–66.
10. Smolina K, Wright FL, Rayner M, Goldacre MG. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovascular Qual Outcomes 2012; 5: 532–40.
11. Bhatt DL, Eagle KA, Ohman EM et al for the REACH Registry Investigators. JAMA. 2010; 304 (12): 1350–7.
12. Jernberg T, Hasvold P, Henriksson M et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J doi: 10.1093/eurheartj/ehu505.
13. Sorenzen R, Gislason GH, Fosbol EL et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 2008; 66: 875–84.
14. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–8.
15. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376162 patients. Am J Med 2012; 9 (125): 882–7.
16. Fox KA, Carruthers KF, Dunbar DR et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755–64.
17. Karetnikova V.N., Evseeva M.V., Kalaeva V.V i dr. Pochechnaia disfunktsiia pri infarkte miokarda s pod"emom segmenta ST: faktory riska, vliianie na prognoz. Serdtse. 2014 (80); 6: 339–46. [in Russian]
18. Karetnikova V.N., Zykov M.V., Kashtalap V.V. i dr. Znachenie pochechnoi disfunktsii dlia gospital'nogo prognoza bol'nykh infarktom miokarda s pod"emom segmenta ST. Serdtse. 2013 (73); 5: 50–6. [in Russian]
19. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation 2002; 106: 1690–5.
20. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350 (15): 1495–504.
21. Rex S et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97–110.
22. Buriachkovskaia L.I., Sumarokov A.B., Uchitel' I.A., Gupalo E.M. Protivovospalitel'noe deistvie klopidogrela pri ateroskleroza. Ratsional'naia farmakoterapiia v kardiologii. 2011; 7 (6): 677–84. [in Russian]
23. Solheim S et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006; 96: 660–4.
24. Chen YG et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J 2006; 119: 32–6.
25. O,Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task force on Practice Guidelines. Circulation 2013; 127 (4): e362–e425.
26. Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–619.
27. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.
28. Husted S, Emanuelsson H, Heptinstall S et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038–47.
29. Yusuf S, Mehta SR, Zhao F et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003; 107: 966–72.
30. Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028–33.
31. Park SJ, Park DW, Kim YH et al. Duration of antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374–82.
32. Lee CW, Ahn JM, Park DW et al. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a randomized, controlled trial. Circulation 2014; 129 (3): 304–12.
33. Valgimigli M, Campo G, Monti M et al. Short-versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125 (16): 2015–26.
34. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 47: 1982–8.
35. Cavender MA, Scirica BM, Bonaca MP et al. Vorapaxar in Patients With Diabetes and Prior MI: Findings from the TRA 2 P-TIMI 50 Trial. doi: 10.1161/CIRCULATIONAHA.114.013774.
36. Chin CT, Roe MT, Fox KA et al. Study design and rationale of a comparison of prasugrel andclopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160: 16–22.
37. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088–92.
38. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.
39. Giustino G, Baber U, Sartori S et al. Duration of dual antiplatelet therapy after drug-eluting stent impantation. J Am Coll Cardiol 2015; 65 (13): 1298–10.
40. Gilard M, Barragan P, Noryani AA et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J Am Coll Cardiol 2015; 65: 777–86.
41. Erlikh A.D. Dvoinaia antitrombotsitarnaia terapiia: neobkhodimost' priverzhennosti k lecheniiu i vozmozhnosti ee povysheniia. Aterotromboz. 2014; 2: 25–33. [in Russian]
42. Bonaca MP, Bhatt D., Cohen M et al for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.
43. Bonaca MP, Bhatt D, Braunwald E et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437–444.e5.
44. Tolpygina S.N., Polianskaia Iu.N., Martsevich S.Iu. Lechenie patsientov s khronicheskoi IBS v real'noi klinicheskoi praktike po dannym registra PROGNOZ IBS (chast' 2). Ratsional'naia farmakoterapiia v kardiologii. 2013; 9 (5): 49–9. [in Russian]
Авторы
О.Л.Барбараш*1,2, В.Н.Каретникова1,2, В.В.Кашталап1,2
1 ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний. 650002, Россия, Кемерово, Сосновый бульвар, д. 6;
2 ГБОУ ВПО Кемеровская медицинская академия Минздрава России. 650036, Россия, Кемерово, ул. Ворошилова, д. 22А
*Olb61@mail.ru
1 Scientific-Research Institute for Complex Issues of Cardiovascular Disease. 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6;
2 Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation. 650036, Russian Federation, Kemerovo, ul. Voroshilova, d. 22A
*Olb61@mail.ru
1 ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний. 650002, Россия, Кемерово, Сосновый бульвар, д. 6;
2 ГБОУ ВПО Кемеровская медицинская академия Минздрава России. 650036, Россия, Кемерово, ул. Ворошилова, д. 22А
*Olb61@mail.ru
________________________________________________
1 Scientific-Research Institute for Complex Issues of Cardiovascular Disease. 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6;
2 Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation. 650036, Russian Federation, Kemerovo, ul. Voroshilova, d. 22A
*Olb61@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.